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The failure of researchers to replicate genetic-association ﬁndings is most commonly attributed to insufﬁcient statistical power, popu-
lation stratiﬁcation, or various forms of between-study heterogeneity or environmental inﬂuences.1 Here, we illustrate another potential
cause for nonreplications that has so far not received much attention in the literature. We illustrate that the strength of a genetic effect
can vary by age, causing ‘‘age-varying associations.’’ If not taken into account during the design and the analysis of a study, age-varying
genetic associations can cause nonreplication. By using the 100K SNP scan of the FraminghamHeart Study, we identiﬁed an age-varying
association between a SNP in ROBO1 and obesity and hypothesized an age-gene interaction. This ﬁnding was followed up in eight in-
dependent samples comprising 13,584 individuals. The association was replicated in ﬁve of the eight studies, showing an age-dependent
relationship (one-sided combined p ¼ 3.92 3 109, combined p value from pediatric cohorts ¼ 2.21 3 108, combined p value from
adult cohorts ¼ 0.00422). Furthermore, this study illustrates that it is difﬁcult for cross-sectional study designs to detect age-varying
associations. If the speciﬁcs of age- or time-varying genetic effects are not considered in the selection of both the follow-up samples
and in the statistical analysis, important genetic associations may be missed.Introduction
It is generally accepted that replication of identiﬁed associ-
ations in other populations is necessary to validate initial
ﬁndings (that is, the differentiation of true-positive from
false-positive results) and possibly generalize them to other
populations. However, genetic-association studies have
faced the challenge of inconsistent replication, both in
the context of genome-wide association (GWA) studies
and, more commonly, in the context of candidate-gene
studies.2–7 Recent technological advances enabling large-
scale SNP genotyping at relatively low cost, the deve-
lopment of several such platforms with polymorphism
content of sufﬁcient density, and the advent of powerful
statistical methods for the analysis of such data have
resulted in the successful implementation of GWA studies
and mapping of complex-trait susceptibility loci in several
diseases, including age-related macular degeneration, dia-
betes, obesity, and inﬂammatory bowel disease.8,9 The
number of whole-genome scans on large cohorts is increas-Theing rapidly, making replication imperative for the detec-
tion of valid associations. A 100K scan in the Framingham
Heart Study (FHS) identiﬁed an association between the
phenotype body mass index (BMI) and a common variant,
a SNP with minor allele frequency of 0.30 located near the
INSIG2 gene (INSIG2). In the original paper by Herbert
et. al3 as well as in subsequent replication attempts by
other groups, the original association between BMI and
the SNP near INSIG2 was conﬁrmed in some but not all
cohorts, emphasizing both the complexity and the chal-
lenges for replications of association ﬁndings for complex
traits.9–14
Difﬁculty in replicating genetic-association ﬁndings is
most commonly attributed to insufﬁcient statistical power,
population stratiﬁcation, or various forms of between-
study heterogeneity, including differences in genetic
ancestry (i.e., linkage-disequilibrium patterns), ascertain-
ment schema (e.g., controls for different diseases are used
to replicate an association for different phenotypes), and
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effects for complex traits can vary by age and that such an
interaction can prevent replications if the age-varying
character of an association is not taken into account in
the selection of both the replication samples and the statis-
tical analysis strategy. Although the importance of age-
dependent genetic effects for BMI has been suggested,15
their incorporation into current genetic analyses is not
common.
The previously mentioned association between obesity,
measured as BMI kg/m2, and a common genetic variant
near INSIG2 was identiﬁed via a scan of 86,604 SNPs
among 923 individuals in the FHS offspring cohort.9
Recently, genotyping of the entire FHS sample with 1322
individuals was completed on the 100K platform, and ge-
netic information for additional 399 subjects became avail-
able. We then reanalyzed the data, using the VanSteen
Screening and Testing algorithm for family data.16 Given
the availability of longitudinal BMI measurements in the
FHS, we selected the family-based association test-princi-
pal components (FBAT-PC) approach, which is particularly
suited to detect both genetic main effects and time-varying
effects without having to make prior assumptions about
the presence of either effect.17 Our reanalysis identiﬁed
a second commongenetic variant (rs1455832) at a different
gene locus intronic to the gene roundabout axon guidance
receptor, homolog 1 (ROBO1) (AHC [MIM 602430]) that
achieved genome-wide signiﬁcance (unadjusted p value
p ¼ 0.000624, Table 1). Because these data were longitudi-
nal in nature (six BMI measurements per person), a proﬁle
plot that illustrates the effect of genotype on BMI over time
was generated (Figure 1). This plot revealed a genetic effect
between rs1455832 and BMI that varies by age (Figure 1).
For the minor allele homozygote (CC), we observe a
gene-age interaction associated with increased BMI that
diminishes after age 45 (see Figure 1).We therefore selected
as our replication hypothesis a gene-age interaction where
the CC genotype is associated with increased BMI until the
age of 45, at which point the effect diminishes.
Table 1. Screening and Testing of SNPs for Association with
Body Mass Index on the Basis of the 86,604 SNP Scan in 1,322
Subjects of the Framingham Heart Study: The Top Ten Powered
SNPs
Power
Rank SNP Allele HWE
Informative
Families
FBAT
p Value
1 rs1439358 1 0.183803 22 0.88141
2 rs1875645 1 0.464993 69 0.886052
3 rs9312225 1 0.446051 70 0.848928
4 rs2134456 1 0.466619 72 0.810328
5 rs10520722 2 0.419401 65 0.592788
6 rs778373 2 0.318246 43 0.835302
7 rs293287 2 0.347734 53 0.228776
8 rs7566605 2 0.36771 49 0.001879
9 rs1455832 1 0.268188 32 0.000624
10 rs10493150 2 0.489362 73 0.662261
The bold indicates the two SNPs that have been identified as significant
with the PBAT screening algorithm.850 The American Journal of Human Genetics 82, 849–858, April 20We then attempted to replicate the association in eight
additional cohorts totaling 13,584 subjects. These cohorts
included studies of unrelated individuals and families, dif-
ferent ethnicities, varying ascertainment conditions, and
different age ranges (childhood, adult). The objective of
the replication effort was the assessment of whether the
age-varying effect that was observed in the FHS was
study-speciﬁc or could be generalized to the other samples.
Further, assuming that the age-varying effect was un-
known before the replication analysis, we assessed whether
the default statistical analysis of the sample would have
detected an age-dependent effect.
Material and Methods
Replication Samples
We used data on 1322 participants from the FHS offspring cohort
in this analysis. Details of the study design, recruitment, and fol-
low up are explained in more detail elsewhere.18–20 In brief, this
cohort consisted of the offspring and spouses of offspring of par-
ticipants in the original FHS cohort, who have been followed pro-
spectively since 1971, and their children. The mean and median
ages at the ﬁrst examination were 31.9 years and 31 years, respec-
tively. Individuals were recruited for this study because they lived
in the town of Framingham,MA, without regard to the presence of
a particular disease. Obesity was documented in BMI, which is
calculated by the division of weight in kilograms by height in
meters squared: kg/m2. Measurements of BMI were taken six times
throughout an average time span of 23.5 years. The second exam-
ination occurred approximately 8 years after the ﬁrst examination,
and subsequent examinations occurred on average every 4 years
thereafter. A total of 116,204 SNPs were initially genotyped, of
which 86,604 were used in the association analyses after the
appropriate exclusions were made.9 The samples were genotyped
with the Affymetrix GeneChip Human Mapping 100K SNP set.
The genotype call rate was 99.1% with no discordance among
replicate samples.
Family-based association analyses were performed with the
FBAT-PCmethodology implemented in PBATon the six longitudi-
nal measures of BMI.17 In the initial analysis, additive, dominant,
and recessive models were all considered. The FBAT-PC methodol-
ogy works optimally over multiple time points when the genetic
effect varies over time and in the presence of environmental corre-
lation. When constructing the overall phenotype, the FBAT-PC
methodology up-weights the time points with heritability evi-
dence in the phenotypes and down-weights the time points
with little evidence of heritability in the phenotypes.
Eight independent study samples were used to replicate the
initial ﬁndings. These study populations were selected to provide
information across a range of ethnicities and age ranges. Replica-
tion populations include families of children diagnosed with
asthma from the Central Valley of Costa Rica (Costa Rica); fami-
lies of children diagnosed with asthma from a North American
clinical trial (CAMP); a child-based sample from Athens, Greece
(Gene Diet Attica Investigation on childhood obesity [GENDAI]);
a population-based sample from Germany (KORA_S4); a popula-
tion-based sample from Iceland (Iceland); and three cohorts of
lean and obese people from Europe (European Sample), the
United States (US sample), and the Merck pharmaceutical com-
pany (Merck).08
Figure 1. Profile Plots of Body Mass
Index by Age for CC and CT or TT Geno-
types in FHS and CAMP
These plots are presented for the two
longitudinal studies that we have, FHS
and CAMP. The left panel illustrates an ini-
tial increase in body mass index (BMI) for
the CC genotype that diminishes by age
30 in the FHS. After age 8, the right panel
also illustrates an increase in BMI associ-
ated with the CC genotype in CAMP. Prior
to this age, our sample is limited in size,
which is illustrated by the initial cross in
genotypes.Costa Rica
The rs1455832 polymorphism was genotyped in 424 nuclear fam-
ilies of children with asthma in the Central Valley of Costa Rica.
Most of the approximately 2.85 million current residents of the
Central Valley descend from approximately 4000 individuals
counted in the census of 1697. Short screening questionnaires
were sent to the parents of 9054 children ages 6 to 14 years
enrolled in 95 schools in the Central Valley of Costa Rica from
February of 2001 to March of 2005. Children were eligible for in-
clusion in the study of parent-child trios if they had physician-
diagnosed asthma, at least two respiratory symptoms (wheezing,
cough, or dyspnea) or a history of asthma attacks in the previous
year, and high probability of having at least six great grandparents
born in the Central Valley of Costa Rica (as determined by the
study genealogist on the basis of the paternal and maternal last
names of each of the child’s parents).21 Phenotypic information
collected from the subjects included measures of weight and
height, from which BMI was calculated. This population was not
ascertained on the basis of morphometric phenotypes. Genotyp-
ing was performed with the Illumina BeadStation 500G system.22
Genotyping completion rate was greater than 99.8% with no
discordancies among replicate genotypes. Because of Mendelian
inconsistencies, nine families were excluded from the analysis.
In total, 409 families had sufﬁcient SNP and BMI information to
be included in the analysis.Written parental consent was obtained
for participating children, for whom written assent was also ob-
tained. The study was approved by the Institutional Review Boards
of the Hospital Nacional de Nin˜os (San Jose´, Costa Rica) and Brig-
ham and Women’s Hospital (Boston, MA).
CAMP
The Childhood Asthma Management Program (CAMP) is a multi-
centered North American clinical trial evaluating the long-term ef-
fect of inhaled antiinﬂammatory medications in children with
mild to moderate asthma. DNA samples were obtained from par-
ticipating children and their parents as previously described.23–25
In brief, children ages 5 through 12 were enrolled between Decem-
ber 1993 and September 1995. Otherwise healthy childrenwere el-
igible for enrollment if they had a diagnosis of asthma as deﬁned
by methacholine hyperreactivity (FEV1PC20 < 12.5 mg/ml) and at
least one of the following criteria for 6 months in the year prior to
enrollment: (1) asthma symptoms at least two times per week, (2)
at least two usages per week of an inhaled bronchodilator, and (3)
use of daily asthma medication. Measures of height and weight
were collected at baseline and throughout the study. Because
chronic inhaled corticosteroid use (one of the three treatment
arms in the CAMP trial) is known to inﬂuence height (and in
turn BMI),25 we restricted the statistical analysis to the baselineThemeasure of BMI when we could not appropriately control for the
treatment arm assignment in another way. When the treatment
arm could be adjusted for properly, we used all repeated measure-
ments. A total of 408 individuals of European descent with BMI
and SNP information were used in the analysis. Genotyping was
performed with the Sequenom system with a genotyping comple-
tion rate of 98%.26 Informed assent and consent were obtained
from the study participants and their parents to collect DNA for
genetic studies. The Institutional Review Board of the Brigham
and Women’s Hospital, as well as those of the other CAMP study
centers, approved the study.
GENDAI
DNA samples were obtained from 1020 school-aged children in
Athens, Greece, as previously described.27 The study group was
composed of children between 9 and 14 years of age from 40 of
593 schools in selected areas of the Athens Attica region. Enroll-
ment began in November 2005 and continued through 2006.
The children were each examined by a physician and surveyed
through parent questionnaires. Exclusions included lack of inter-
est, refusal, chronic or acute illness, absence from school, reloca-
tion, or incomplete data. Data collected include anthropometrics,
a fasting blood sample, 24 hr dietary and physical activity recall,
food frequency questionnaire, and questionnaires on meal pat-
terns, lifestyle, personal, and family characteristics. Genotyping
was completed by an allele-speciﬁc primer extension of ampliﬁed
products with detection bymatrix-assisted laser desorption ioniza-
tion time-of-ﬂight mass spectroscopy with a Sequenom platform.
Genotyping call rate was 99.6% on 796 samples with adequate
DNA concentration, showing no consensus errors. The IRB of
Children’s Hospital Boston and of Harokopio University and the
Greek Ministry of Education approved the study. Subjects with
poor genotyping quality were excluded. In total, 796 subjects
were included in the statistical analysis.
KORA_S4
This is the fourth population-based survey (S4) of the platform
‘‘Kooperative Gesundheitsforschung in der Region Augsburg’’
(KORA_S4). Details about the study, the BMI distribution and its
dependence upon gender and age can be found elsewhere.28 In
brief, this survey was conducted during the years 1999–2001.
The sample was drawn to represent the population of the city of
Augsburg and surrounding counties in a stratiﬁed fashion by 10
year age groups and by gender. Subjects were recruited via registry,
were of German nationality, 25–75 years of age, 50% females, and
mostly white Europeans (99%). Anthropometric measurements
including weight and height were assessed according to the
WHO MONICA protocol by trained staff.28 The association was
analyzed in all subjects with genotype and phenotype available,American Journal of Human Genetics 82, 849–858, April 2008 851
yielding data on 3861 subjects. Genotyping was performed with
MALDITOF MS (Sequenom, Mass ARRAY System, San Diego,
CA).29 The genotype call rate was 95.84% with no discordancies
among replicate samples. All study participants gave informed
written consent according to the ethics committee of the Bavarian
Medical Association and every attempt was made to ensure
anonymity of the participants.
Iceland
DNA samples were obtained from a population-based group of
4865 Icelanders. Any possible relatedness between Icelanders
was accounted for as described previously.10 The study group
was composed of individuals who participated in studies of the ge-
netic etiology of cardiovascular and metabolic diseases, and the
majority of these subjects were recruited as unaffected relatives
of subjects or as controls and did not have any history ofmetabolic
or cardiovascular diseases. All participants in the study signed in-
formed consent. All personal identiﬁers associated with tissue
samples, clinical information, and genealogy were encrypted by
the Data Protection Authority (DPA), with a third-party encryp-
tion system in which DPA maintains the code.30 The genotyping
procedure has been previously described.31 Genotype call rate
was 93.72%. Ethical approval for the present study was granted
by the National Bioethics Committee (NBC reference number
01-033) and the Icelandic DPA.
The p values and conﬁdence intervals were adjusted for related-
ness of the Icelandic individuals with simulations as previously de-
scribed.32 Genotypes for the causal SNP were simulated through
the Icelandic Genealogy Database, based on more than 600,000
Icelanders, and the association test was performed. This procedure
was repeated 50,000 times to generate an empirical distribution,
from which the standard deviation under the null hypothesis of
no association was generated and used to adjust both the p value
and the conﬁdence interval.
European and US Cohorts
The rs1455832 polymorphism was genotyped in obese and lean
Caucasian subjects from Poland (EUROPEAN) and the United
States (US) with data provided by Genomics Collaborative. Obese
subjects were selected from among individuals in the 90th97th
percentile of the BMI distribution, and lean subjects were selected
from the 5th–12th percentile. Such distributions were determined
with information on gender, country of origin, and age by decade
as previously described.2 The obese and lean subjects were
matched by gender, decade of age, and country of origin of grand-
parents. Genotyping completion rates were 99.0% for the Euro-
pean sample and 99.6% for the US sample. There were a total of
701 cases and 331 controls in the European sample and 1218 cases
and 624 controls in the US sample. Ages for these samples range
from 31 to 70 years. Approval for this work was obtained from
the IRB at Children’s Hospital Boston.
Merck
The rs1455832 polymorphism was genotyped in a case-control
study in which the cases had been recruited as part of a multicen-
ter, double-blind, randomized, placebo-controlled study. Obese
patients with BMI 30-43 kg/m2 and between the ages of 21 and
65 who met other entry criteria were eligible to participate. Only
white patients were considered for the genetic study. Prior to ran-
domization, there was a 2 week single-blind placebo run-in period.
The BMI measures used in the genetic analysis were collected at
the end of the run-in period and before any drug was administered
as part of the trial. Genetic and phenotypic information was col-
lected on a total of 275 cases. The controls were acquired from
GHC from a databank of individuals selected and consented for852 The American Journal of Human Genetics 82, 849–858, April 20scientiﬁc study. We selected and genotyped 547 lean, healthy,
white controls equally split between males and females, with
BMI less than 25 and age greater than 50. In addition, the controls
were selected because they were free of all forms of diabetes,
cardiovascular disease, and obesity, and they had no ﬁrst-degree
relatives with these diseases. All samples and patient data were
handled in accordance with the policies and procedures approved
by a Merck IRB.
Statistical Methods
The PBAT screening approach, as described previously, was imple-
mented in the 100K analysis of the FHS data to minimize the mul-
tiple comparisons problem.9,16 In summay, the PBAT screening
and testing algorithm follows three steps: (1) Power is calculated
for all SNPs with the conditional mean model, (2) the SNPs are
rank ordered according to the power calculations, (3) the ten
SNPs with the greatest power are selected, and (4) statistical anal-
yses are performed on the selected subset of SNPs. We employed
the PBAT screen while using FBAT-PC, which constructs one max-
imally heritable BMI component for each SNP from the six mea-
sures of BMI. Family-based association analysis is then applied to
the univariate BMI phenotype.17 Golden Helix PBAT was used
to perform these analyses.
Replication Analyses
We performed two analyses for each replication cohort: (1) a
‘‘uniform-analysis’’ approach that is the same for all eight replica-
tion cohorts and tests for both a geneticmain effect and a gene-age
interaction and (2) a ‘‘design-speciﬁc analysis’’ of the genetic main
effect alone. When we refer to the design-speciﬁc analysis, we
mean the default analysis that would typically be performed for
a given study design. For the uniform analysis, a standard linear re-
gression adjusting for the covariates age and gender was run, with
genotype and genotype-by-age interactions as the primary predic-
tors of interest and BMI as the response variable. The linear model
used for these analyses was BMI ¼ b0 þ b1genotype þ b2age þ
b3sex þ b4age*genotype þ 3, where genotype ¼ 1 if CC and geno-
type ¼ 0 otherwise. Obesity affection status was used as an addi-
tional covariate for the case-control studies. In the CAMP study,
a multivariate longitudinal regression analysis was performed in
which the 14 BMI measures were the dependent variable. All of
the independent variables listed above were included, with the ad-
dition of an indicator variable for asthma treatment arm, because
CAMP was part of a clinical trial. In all models, the genotype was
modeled in a recessive fashion to replicate the initial ﬁndings.
F tests were used to evaluate the signiﬁcance of both the main
genetic effect and the age-by-genotype interaction term.
Based on the results of this analysis, a study was considered
either a replication or a nonreplication. If the parameter estimate
for the gene-age interaction variable was signiﬁcant (a < 0.05), as-
sociated with the recessive genotype (CC), and the parameter esti-
mate was negative (indicating a decrease in BMI with older ages for
the recessive genotype), the study was called a replication. Other-
wise, it was referred to as a ‘‘nonreplication.’’ However, this created
a dilemma for the pediatric cohorts (CAMP, Costa Rica, GENDAI)
that were included in this replication attempt. The hypothesis of
a gene-age interaction for subjects younger than 45 years was
generated on the basis of the FHS, whose youngest subjects were
16–20 years old, whereas the pediatric cohorts covered an age
range of 4–18 years. Because the age ranges of the pediatric cohorts
and the FHS overlapped for only 2 years and a negative estimate08
for the gene-age interaction would have meant an increase in BMI
with younger ages for the recessive genotype, a peak for the asso-
ciation with BMI must occur in the age range below 20 years. One
could envision three hypotheses: (1) The peak age of association is
at birth or a very early age, (2) the peak association age coincides
with the ages of the pediatric cohorts, or (3) the peak association
age is around 20, when the pediatric cohorts and the FHS overlap.
Testing and distinguishing of all three hypotheses for the pediatric
cohorts is technically challenging and requires larger sample sizes
than those we have at hand. These three hypotheses have one
thing in common that makes them consistent with the FHS ﬁnd-
ings: They predict higher BMI values for the recessive genotypes
in the 15–20 year age range. We therefore considered a pediatric
cohort to be a replication of the FHS ﬁnding if its interaction
term was signiﬁcant (a < 0.05) and the interaction had a positive
parameter estimate associated with the recessive genotype (CC).
A Fisher’s combined p value was calculated to determine the
overall evidence for an age-by-genotype interaction for all models.
Fisher developed a method for combining p values from k inde-
pendent tests by summing over the log of the p value and multi-
plying the sum by 2. This statistic follows a chi-square distribu-
tion with 2k degrees of freedom. In this calculation, one-sided
p values were used to account for scenarios in which the trend
tended in the opposite direction.
Standard design-based analyses were performed for each of the
replicate cohorts as follows. In the two family-based studies, Costa
Rica and CAMP, we performed family-based association analysis of
standardized BMI with age and sex as covariates, assuming a reces-
sive genetic model, with Golden Helix PBAT. The standardization
used in these analyses was recommended by the Center for Disease
Control (CDC; see CDC-Deﬁned BMI for Adolescents and Chil-
dren in the Web Resources) and accounts for the effect of age
and gender on BMI throughout childhood and adolescence. We
restricted our analysis to the baseline measure of BMI in CAMP be-
cause one of the three treatment arms of the trial would have to be
removed because of the known association of steroid use with
BMI, and this would greatly reduce the sample size and therefore
the power for this study. For the three case-control studies (Euro-
pean, US, and Merck), a logistic regression analysis of case-control
status (obese and nonobese subjects) on rs1455832 was used. We
performed the logistic regression analysis assuming a recessive
model with a main genetic effect and adjusting for age and sex.
Because the European and US samples were matched on age and
gender, the addition of the variables as covariates contributed little
to the analysis. In the population-based designs (KORA, Iceland,
and GENDAI), we performed linear regression analysis of BMI on
rs1455832 assuming a recessive genetic model and adjusting for
age and sex. The Iceland analyses were performed with log-trans-
formed BMI. No pooled analyses of the replication samples were
performed because we did not have access to all of the individual
genotype data.
Results
Preliminary Association of rs1455832
in the 100K FHS Scan
As previously reported,9 a total of 86,604 SNPs were
screened for an association with BMI in the FHS. These
SNPs were subsequently genotyped in an additional 399
individuals, totaling 1322 subjects. We then reanalyzedThethe data with the same methodology from the original
paper; the results for the top ten powered SNPs are pre-
sented in Table 1. Of these, two SNPs reached genome-
wide signiﬁcance (unadjusted p value for rs7566605 ¼
0.002, unadjusted p value for rs1455832 ¼ 0.0006). Details
of the signiﬁcant association between rs7566605 and obe-
sity were described in the previous report.9 SNP rs1455832
is also common (minor allele frequency [MAF] ¼ 0.271)
and did not deviate from Hardy-Weinberg Equilibrium
(HWE) (p ¼ 0.27). SNP rs1455832 is located in intron 1
of the ROBO1 gene, which contains 30 exons. Of the addi-
tional 26 SNPs that were genotyped in the ROBO1 gene, 16
SNPs had allele frequencies that resulted in a large enough
sample to evaluate genetic associations (the number of in-
formative families greater than 20). The two SNPs adjacent
to rs1455832 also had signiﬁcant associations with BMI
(p value for rs1455824 ¼ 0.0092, p value for rs2311350 ¼
0.0181); however, this is not surprising because linkage dis-
equilibrium exists between rs1455832 and both of these
SNPs (r2 ¼ 0.81). Details of the age-dependent relationship
between BMI and the rs1455832 genotypes in the FHS
cohort across a 50 year age range are presented in the ﬁrst
graph of Figure 1. In this analysis, we observed a strong
age-varying genetic association in which the CC genotype
was associated with increased BMI compared with the CT
or TT genotypes until age 45 years, when this effect dimin-
ishes. Not surprisingly, the signiﬁcance of themain genetic
effect diminishes after an interaction term is added to the
regression model, because this interaction term captures
the age-dependent effect (Table 2).
Replication Studies in Eight Independent Samples
To validate this initial age-dependent association (i.e.,
age-by-genotype interaction with BMI) ﬁnding between
rs1455832 and BMI, as well as assess its generalizability
to other populations, we genotyped this variant and tested
for evidence of association in eight independent popula-
tions. Descriptive summaries of the eight replication
cohorts are provided in Table 3. Despite different ancestral
histories, the allele frequency was similar across popula-
tions, ranging from 0.211 in Costa Rica to 0.289 in Iceland.
Genotype distributions were in Hardy-Weinberg equilib-
rium in all eight populations.
For the uniform analysis across all replication studies, we
performed a population-based linear regression analysis
with an age-by-genotype interaction term, with a recessive
model. The analysis was restricted to individuals younger
than 45.
A summary of the main genetic effect and gene-age
interaction for the age-varying effect on BMI is provided
in Table 2. In all replication studies, with the exception
of CAMP, the main genetic effect was not signiﬁcant
when an age-by-genotype interaction term was included
in the model. In CAMP, the CC genotype was associated
with an increased BMI compared with the CT or TT geno-
type. As illustrated in the second graph in Figure 1, this ef-
fect is not evident in the early age ranges but is apparentAmerican Journal of Human Genetics 82, 849–858, April 2008 853
Table 2. Findings in Replication Samples
Study
p Value
Main Effect
Main Genetic
Effect Estimate
p Value
Interaction
Interaction
Effect Estimate
Direction of Interaction
Effect Estimate Necessary
for Replication
Genotype Associated
with Increased BMI
at Earlier Ages Replication
FHS 0.97 3.01 0.018 0.073 CC Initial Finding
Pediatric Studies
CAMPa <0.001 7.83 2 3 109 0.838 Positive CC Replication
Costa Rica 0.278 5.29 0.044 0.429 Positive CC Replication
GENDAI 0.311 9.36 0.85 0.865 Positive CT or TT Nonreplication
Adult Studies
US 0.464 3.06 0.05 0.025 Negative CC Replication
European 0.870 1.62 0.02 0.053 Negative CC Replication
Merck 0.473 4.35 0.003 0.067 Negative CC Replication
KORA_S4 0.481 2.97 0.97 0.075 Negative CT or TT Nonreplication
Iceland 0.265 0.96 0.91 0.020 Negative CT or TT Nonreplication
Standard linear regression analysis for all studies including a main genetic effect term and a genotype-by-age interaction term.
a Included treatment arm as a covariate.after age 10. This graph illustrates the relationship between
BMI and the rs1455832 genotypes in the CAMP cohort
across a 10 year age range, where 14 repeated measures of
BMI were used in a multivariate regression model for
each individual.
Replications of the FHS ﬁnding must meet three criteria:
(1) The interaction term must be signiﬁcant (a ¼ 0.05), (2)
the overall associated genotype must be consistent with
the FHS (i.e., during the time frame in which we hypothe-
size an effect, the CC genotype is associated with an in-
creased BMI), and (3) the interaction parameter estimate
must be positive for pediatric cohorts or negative for adult
cohorts. Five of the eight cohorts met these criteria: US,
European, Merck, CAMP, and Costa Rica. Signiﬁcant age-
by-genotype interactions were observed in three adult
cohorts whose age ranges match the FHS: US, European,
and Merck. In these studies, the parameter estimate for
the interaction variable is slightly negative, which is in
the same direction and approximately the samemagnitude
of the effect observed in the FHS. This is to be expected be-
cause their age ranges are similar to those of the initial854 The American Journal of Human Genetics 82, 849–858, April 20study. Of the pediatric cohorts, CAMP and Costa Rica rep-
licated the FHS ﬁndings. As expected for very young ages,
under the alternative hypothesis of an age-dependent ge-
netic effect, the interaction parameter estimate for both
of these studies was positive, which is in the opposite direc-
tion from the adult cohorts. For all ﬁve replications, the CC
genotype was associated with an increased BMI (p < 0.05)
during the time frame of interest. In sum, these studies re-
ﬂect a stronger increase in BMI for the recessive genotype
at younger ages for the pediatric cohorts and the diminish-
ing effect of the recessive genotype in the adult cohorts. As
discussed above, these ﬁve studies are considered valid
replications of the initial ﬁnding under the alternative
hypothesis of an age-dependent genetic effect.
Despite the lack of evidence for interaction in the Ice-
land, KORA_S4, and GENDAI cohorts (Iceland p ¼ 0.910,
KORA_S4 p ¼ 0.968, GENDAI p ¼ 0.851), the one-sided
Fisher’s combined p value for the age-dependent relation-
ship in all replicate samples was highly signiﬁcant (p ¼
3.92 3 109). For the pediatric and adult cohorts sepa-
rately, the combined p values were 2.21 3 108 andTable 3. Descriptive Statistics on Replication Cohorts
Study Design Sample Size
Sample
Size% 50
Years
HWE p
Valuea MAFb
Average Age
(Range)
Average
BMI (Range)
Percent
Male
Costa Rica Family based 409 Trios 409 0.99 0.211 9.1 (6.0 – 14.2) 17.9 (11.3–32.8) 62.6
CAMP Family based 408 Trios 408 0.95 0.269 8.7 (5.2 – 17.5) 17.8 (12.7–28.6) 62.3
GENDAI Population based 796 796 0.89 0.240 11.1 (9.9 – 13.6) 20.2 (12.9–35.9) 52.8
KORA_S4 Population based 3861 2053 0.51 0.269 49.2 (25 – 74) 27.2 (15.8–55.1) 49.0
Iceland Population based 4865 2161 0.92 0.289 53.3 (14 – 93) 27.3 (13.7–60.2) 47.7
European
Sample
Case control 1031 (700 cases) 286 0.90 0.235 55.7 (31 – 70) Cases: 21.4 (19.9–22.7),
Controls: 31.7 (27.8–35.3)
47.0
US Sample Case control 1842 (1218 cases) 401 0.30 0.273 57.0 (31 – 70) Cases: 36.9 (32.3–43.3),
Controls: 21.5 (19.3–23.1)
45.6
Merck Case control 422 (181 cases) 201 0.61 0.271 52.3 (40 – 60) Cases: 34.3 (29.8–40.9),
Controls: 22.3 (12.9–24.9)
39.6
a Reported for parents of affected individuals in family-based studies, for control subjects in case-control studies, and for all subjects in population-based
studies.
b Minor allele frequency.08
0.00422, respectively. In these calculations, information
from GENDAI, KORA_S4, and Iceland cohorts do not con-
tribute positively to this calculation because the direction
of the association was opposite. For the computation of
the combined p value, we accounted for the effect in the
opposite direction by using one-sided p values. Because
Fisher’s method of combining p values is sensitive to
highly signiﬁcant results (which we have in the CAMP
sample), we recalculated the combined p value eight times,
each time removing one of the replication studies. The
overall signiﬁcance of the result did not depend on the
ﬁndings from any individual replication sample because
the combined p value remained signiﬁcant at an a level
of 0.01 when any single replication sample was removed
from the analysis. It is apparent that the results from the
CAMP study are highly signiﬁcant and thus highly inﬂu-
ential on the overall ﬁndings. However, if the CAMP study
were completely removed from the analysis, all results and
conclusions would remain the same, with the only differ-
ence being the magnitude of the combined p value (p ¼
0.0037). To assure that the data from the CAMP study are
not spurious, we thoroughly checked the genotyping and
analysis methods used. We found the quality of these
data to be excellent and therefore have kept this sample
in the paper.
In addition to the uniform analysis approach we used for
all studies, standard study-design-speciﬁc analyses were
conducted, as well. These analyses were focused only on
genetic main effects. The analyses were performed for the
family-based, case-control, and population-based cohorts
Table 4. Findings in Replication Samples for the Main
Genetic Effect: Analysis by Study Design
Study Design and Study Test
p Value for Main
Genetic Effecta
Associated
Genotypeb
Family-Based Studies
Costa Rica PBAT 0.060 CC
CAMP PBAT 0.017 CC
Case-Control Studies
European Logistic
regression
0.920 N/A
US Logistic
regression
0.311 N/A
Merck Logistic
regression
0.665 N/A
Population-Based Studies
GENDAI F test 0.679 N/A
KORA_S4 F test 0.848 N/A
Iceland F test 0.596 N/A
The family-based studies were analyzed with a standard family-based asso-
ciation test. The case-control studies were analyzed with a standard logistic
regression with obese or lean status as the outcome variables and genotype,
age, and gender as covariates. The population-based studies were per-
formed over the entire sample and stratified on age. A linear regression
with genotype as the main predictor variable and BMI as the outcome
variable was performed.
a p value with a recessive model.
b Genotype associated with increased BMI is only presented when the
finding reaches nominal significance at an a level of 0.10.Theseparately. These ﬁndings are summarized in Table 4.
With Golden Helix PBAT for the family-based designs,
the association between standardized BMI and rs1455832
was of borderline statistical signiﬁcance (p¼ 0.06) in 63 in-
formative families in Costa Rica and tended in the risk di-
rection. This association was found to be signiﬁcant in the
CAMP cohort with 96 informative families (p ¼ 0.017).
Therefore, the main genetic effect was detected in both
of these child and/or adolescent samples. Logistic regres-
sion analyses did not result in a signiﬁcant main genetic
effect for any of the case control studies. In the KORA_S4
cohort, there was no association between the genotype
and BMI among all subjects (p ¼ 0.848). In the Iceland co-
hort, the genetic effect was also not signiﬁcant (p¼ 0.596).
No signiﬁcant association was observed between genotype
and BMI with the GENDAI cohort (p ¼ 0.679).
Discussion
We initially observed an age-varying (i.e., age-by-genotype
interaction) association between BMI and rs1455832 in
the FHS cohort, where the CC genotype was associated
with increased BMI early in life and diminished over
time. The initial ﬁnding was arrived at with the FBAT-PC
approach, which is particularly suited to detect both ge-
netic main effects and time-dependent effects. We sought
to replicate the age-varying association in eight indepen-
dent replication samples. The age-by-rs1455832 interac-
tion with the same directional effect was observed in ﬁve
of the eight replicate samples with statistically signiﬁcant
results. These replication samples each had varying demo-
graphic properties, ascertainment conditions, and study
designs. Notably, the genetic association was not detect-
able in all populations (three of which had no signiﬁcant
age-by- rs1455832 interactions); however, the combined
p value from all of the replication samples indicates a sig-
niﬁcant overall association. It is also important to note
that, in all of the replication samples except CAMP, the ge-
netic association effect would not have been detected had
we only been testing for a main genetic effect and not an
age-by-rs1455832 interaction.
One important aspect in identifying associations of in-
terest is selecting replication samples in the age range of
the effect that was initially observed. Therefore, if we are
simply interested in evaluating the observed main genetic
effect, samples in which all individuals are less than 30
years of age are ideal. If the cohort includes individuals
younger and older than 30 years of age and an interaction
term is not incorporated into the analysis, the genetic
effect may be missed. In cohorts whose members are all
younger than 30 years, we would expect to observe the
main genetic effect. The two family-based replication sam-
ples, CAMP and Costa Rica, identiﬁed the genetic associa-
tion with at least marginal signiﬁcance (a< 0.10), whether
or not the time-dependent effect was considered. This is
probably because both of these studies recruited childrenAmerican Journal of Human Genetics 82, 849–858, April 2008 855
and adolescents and are therefore well-powered to detect
the association. The proﬁle plot for the CAMP study sug-
gests that the genetic effect is less clear at very young
ages (less than 10 years). This might point toward an effect
starting at or after puberty, and it might be speculated that
hormone status plays a role. In contrast to the two family-
based studies, the GENDAI cohort does not show the main
genetic effect or the interaction. This could be attributable
to the small age range in GENDAI; most subjects were
either age 11 or 12, making it very difﬁcult to detect
a gene-age interaction.
We also observed that the ﬁndings are sensitive to how
strongly the sample was ascertained for obesity. A big
advantage of population-based studies (FHS, KORA_S4,
Iceland, and GENDAI) is that their phenotypic range is
not restricted through the ascertainment condition,
making them ideal samples in which to test for gene-age ef-
fects. Although the CAMP and Costa Rica samples were as-
certained for asthma, which has a weak association with
obesity, the asthma cases are mild enough and the
asthma-obesity relationship tenuous enough to conclude
that neither of these samples was ascertained for obesity.
Therefore FHS, KORA_S4, Iceland, GENDAI, CAMP, and
Costa Rica can essentially be thought of as unbiased cohorts
for BMI. When looking for an age-dependent relationship
between a disease and SNP, the analysis of these cohorts is
straightforward. In contrast, the analytic strategy to detect
interaction with age is less clear for the Merck, European,
and US samples, all of which were ascertained for obesity.
When the data are ascertained by the case-control status,
the phenotypic variation is reduced so substantially that
the interaction effect is obscured. Therefore, case-control
studies are better suited to detect main effects, but their
design is limited to detect interactions.
These analyses also illustrate that longitudinal pheno-
typic measures provide more power to detect modest age-
related effects in genetic studies. Age-dependent effects
can easily be missed if only one time point is collected, be-
cause the data collection may not occur when the genetic
effect is strongest. Longitudinal measures are also a power-
ful way to increase the power of genetic studies, which is
important when the genetic effects are modest. In our
analyses, the two strongest effects were observed with
the FHS and CAMP cohorts, both of which had many re-
peated-measures of BMI at different ages. Population-based
cohorts like the FHS, with longitudinal data during the
proper time period, seem to be optimal for identifying
age-varying genetic effects. Although it is true that such
a model can be estimated with cohort or case-control
data at a single time point, the statistical power of such
a model to detect signiﬁcant genetic associations, particu-
larly gene-time interactions, is much higher when longitu-
dinal data are available.
A potential cause for the observed age-related genetic ef-
fects could be period effects; however, given the relatively
consistent ﬁndings across several samples collected at dif-
ferent time points (some of themmore than 40 years apart)856 The American Journal of Human Genetics 82, 849–858, April 20and in different geographical locations (US, Europe,
Iceland), it is unlikely that the age-by-genotype interaction
is an artifact of a cohort effect.
ROBO1 encodes for a receptor that is a member of the
neural cell adhesion molecule family and is highly
conserved. High tissue expression is found in brain, co-
chlea, mouth, adipose, and embryonic tissue (UniGene
Hs. 13640). In humans, the gene maps on chromosome
3p12, and inactivating mutations were found in lung,
breast, and kidney cancer. Genetic variations within the
ROBO1 gene were reported to be associated with dyslexia.33
We can only speculate whether ROBO1 plays a role in obe-
sity. ROBO1 is expressed in adipose tissue, though its func-
tion in this tissue is completely unknown.
As important ﬁndings arise from the increasing number
of genetic-association studies and subsequent replication
attempts become more common, it is vital that replication
attempts carefully examine speciﬁc attributes of the initial
study. Among necessary considerations are possible age-
dependent effects from the initial association ﬁndings. In
a common disease such as obesity, population-based sam-
ples are better suited than highly ascertained studies to rep-
licate the initial ﬁndings. In conclusion, an age-genotype
interaction has caused apparent inconsistencies in the at-
tempts to replicate the ﬁnding of an association between
rs1455832 and obesity in the FHS. This highlights the pit-
falls of replication in cohorts with ascertainment condi-
tions and age ranges different than those of the original
study. Population-based samples with longitudinal data
have greater statistical power to detect genetic effects
that vary in strength by age. Given that current genotyp-
ing technology has made genotyping affordable in large-
scale population-based studies, such cohorts seem to be
ideal for both the discovery of new genetic effects and their
replication.
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